Delineating the mode of action of adenosine A1 receptor allosteric modulators

Molecular Pharmacology

Volumn 78, Issue 3, 2010, Pages 444-455

  Valant, Celine ^a   Aurelio, Luigi ^a   Urmaliya, Vijay B ^a   White, Paul ^a   Scammells, Peter J ^a   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO (4,5,6,7 TETRAHYDROBENZO[B]THIOPHEN 3 YL) (4 CHLOROPHENYL)METHANONE; 2 AMINO 3 (3,4 DICHLOROBENZOYL) 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE; 2 AMINO 4 (3,5 BIS(TRIFLUOROMETHYL)PHENYL)THIOPHEN 3 YL)(PHENYL)METHANONE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 2 CHLORO N6 [3 H]CYCLOPENTYLADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ATROPINE; BENZOTHIOPHENE DERIVATIVE; CARBACHOL; PHENYLISOPROPYLADENOSINE; PROTEIN INHIBITOR; T 62; TERT BUTYL 2 AMINO 3 (4 CHLOROBENZOYL) 7,8 DIHYDRO 4H THIENO[2,3 D]AZEPINE 6(5H) CARBOXYLATE; UNCLASSIFIED DRUG; VCP 333; VCP 520; [3 H] 8 CYCLOPENTYL 1,3 DIPROPYLXANTHIN; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE; 1,3-DIPROPYLXANTHINE; ADENOSINE; G PROTEIN COUPLED RECEPTOR; LIGAND; N-(1-METHYL-2-PHENYLETHYL)ADENOSINE; XANTHINE DERIVATIVE;

ALLOSTERISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; ANALOGS AND DERIVATIVES; BINDING SITE; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

ADENOSINE; ALLOSTERIC SITE; LIGANDS; RECEPTOR, ADENOSINE A1; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; XANTHINES;

EID: 77956245258     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.064568     Document Type: Article

References (38)

1. Aurelio L, Figler H, Flynn BL, Linden J, and Scammells PJ (2008) 5-Substituted 2-aminothiophenes as A1 adenosine receptor allosteric enhancers. Bioorg Med Chem 16:1319-1327.
2. Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, and Scammells PJ (2009) Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J Med Chem 52:4543-4547.
3. Baraldi PG, Iaconinoto MA, Moorman AR, Carrion MD, Cara CL, Preti D, López OC, Fruttarolo F, Tabrizi MA, and Romagnoli R (2007) Allosteric enhancers for A1 adenosine receptor. Mini Rev Med Chem 7:559-569.
4. 3H] (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-(4- chlorophenyl)-methanone, the first radiolabelled adenosine A1 allosteric enhancer. Bioorg Med Chem Lett 16:1402-1404.
5. Baraldi PG, Zaid AN, Lampronti I, Fruttarolo F, Pavani MG, Tabrizi MA, Shryock JC, Leung E, and Romagnoli R (2000) Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. Bioorg Med Chem Lett 10:1953-1957.
6. Bhattacharya S and Linden J (1995) The allosteric enhancer, PD 81,723, stabilizes human A1 adenosine receptor coupling to G proteins. Biochim Biophys Acta 1265:15-21.
7. Bruns RF and Fergus JH (1990) Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38:939-949.
8. Bruns RF, Fergus JH, Coughenour LL, Courtland GG, Pugsley TA, Dodd JH, and Tinney FJ (1990) Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38:950-958.
9. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Childers SR, Li X, Xiao R, and Eisenach JC (2005) Allosteric modulation of adenosine A1 receptor coupling to G-proteins in brain. J Neurochem 93:715-723.
11. Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol Sci 19:351-357.
12. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
13. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
14. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
15. Elzein E and Zablocki J (2008) A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 17:1901-1910.
16. Ferguson GN, Valant C, Horne J, Figler H, Flynn BL, Linden J, Chalmers DK, Sexton PM, Christopoulos A, and Scammells PJ (2008) 2-aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists. J Med Chem 51:6165-6172.
17. Figler H, Olsson RA, and Linden J (2003) Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. Mol Pharmacol 64:1557-1564.
18. Gao ZG and Jacobson KA (2007) Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 12:479-492.
19. Gregory KJ, Hall NE, Tobin AB, Sexton PM, and Christopoulos A (2010) A Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285:7459-7474.
20. Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58:1412-1423.
21. Kenakin TP (2009) '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30:460-469.
22. Kostenis E and Mohr K (1996) Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci 17:280-283.
23. Lagerström MC and Schiöth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7:339-357.
24. Latini S, Bordoni F, Pedata F, and Corradetti R (1999) Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br J Pharmacol 127:729-739.
25. Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
26. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28:382-389.
27. Lütjens H, Zickgraf A, Figler H, Linden J, Olsson RA, and Scammells PJ (2003) 2-Amino-3-benzoylthiophene allosteric enhancers of A1 adenosine agonist binding: new 3, 4-, and 5-modifications. J Med Chem 46:1870-1877.
28. May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM, and Christopoulos A (2007a) Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol Pharmacol 72:463-476.
29. May LT, Leach K, Sexton PM, and Christopoulos A (2007b) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
30. May LT, Sexton PM, and Christopoulos A (2005) Effects of urea pretreatment on the binding properties of adenosine A1 receptors. Br J Pharmacol 146:1119-1129.
31. Musser B, Mudumbi RV, Liu J, Olson RD, and Vestal RE (1999) Adenosine A1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723. J Pharmacol Exp Ther 288:446-454.
32. Nakanishi M, Tahara T, Araki K, Shiroki M, and Tsumagari T (1973) Studies on psychotropic drugs. 18. Synthesis and structure-activity relationships of 5-phenyl-1,3-dihydro-2H-thieno(2,3-e) (1,4) diazepin-2-ones. J Med Chem 16:214-219.
33. Nikolakopoulos G, Figler H, Linden J, and Scammells PJ (2006) 2-Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers. Bioorg Med Chem 14:2358-2365.
34. Overington JP, Al-Lazikani B, and Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993-996.
35. Rudolphi KA, Schubert P, Parkinson FE, and Fredholm BB (1992) Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci 13:439-445.
36. Stewart GD, Valant C, Dowell SJ, Mijaljica D, Devenish RJ, Scammells PJ, Sexton PM, and Christopoulos A (2009) Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity. J Pharmacol Exp Ther 331:277-286.
37. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
38. van der Klein PA, Kourounakis AP, and IJzerman AP (1999) Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. J Med Chem 42:3629-3635.